Organon Management

Management Kriterienprüfungen 3/4

Organon CEO ist Kevin Ali , ernannt in Jun 2021, hat eine Amtszeit von 3.42 Jahren. Die jährliche Gesamtvergütung beträgt $14.83M , bestehend aus 8.4% Gehalt und 91.6% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.056% der Aktien des Unternehmens, im Wert von $2.21M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.4 Jahre bzw. 3.4 Jahre.

Wichtige Informationen

Kevin Ali

Geschäftsführender

US$14.8m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	8.4%
Amtszeit als Geschäftsführer	3.4yrs
Eigentum des Geschäftsführers	0.06%
Durchschnittliche Amtszeit des Managements	3.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.4yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Kevin Ali im Vergleich zu den Einnahmen von Organon verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	US$1b
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	US$15m	US$1m	US$1b
Sep 30 2023	n/a	n/a	US$585m
Jun 30 2023	n/a	n/a	US$754m
Mar 31 2023	n/a	n/a	US$746m
Dec 31 2022	US$14m	US$1m	US$917m
Sep 30 2022	n/a	n/a	US$1b
Jun 30 2022	n/a	n/a	US$1b
Mar 31 2022	n/a	n/a	US$1b
Dec 31 2021	US$19m	US$1m	US$1b

Vergütung im Vergleich zum Markt: KevinDie Gesamtvergütung ($USD14.83M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt UK ($USD2.69M).

Entschädigung vs. Einkommen: KevinDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Kevin Ali (64 yo)

3.4yrs

Amtszeit

US$14,832,272

Vergütung

Mr. Kevin Ali is Chief Executive Officer and Director of Organon & Co. since June 2, 2021. Mr. Ali served as the President of Global Enterprise Portfolio Strategy at Merck & Co., Inc. from 2019 to 2021 and...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Kevin Ali	CEO & Director	3.4yrs	US$14.83m	0.056% $ 2.2m
Matthew Walsh	Executive VP & CFO	3.4yrs	US$5.21m	0.036% $ 1.4m
Kirke Weaver	Executive VP	1.8yrs	US$3.19m	0.011% $ 445.5k
Susanne Fiedler	Executive VP & Chief Commercial Officer	3.8yrs	US$3.84m	0.021% $ 811.4k
Joseph Morrissey	Executive VP and Head of Manufacturing & Supply	3.4yrs	US$3.74m	0.017% $ 655.2k
Rachel Stahler	Executive VP & Chief Information Officer	3.4yrs	keine Daten	0.019% $ 767.0k
Jennifer Halchak	Head of Investor Relations	3.8yrs	keine Daten	keine Daten
Susan O'Neal	Chief Ethics & Compliance Officer	no data	keine Daten	keine Daten
Rebecca Edwards	Chief Communications Officer	no data	keine Daten	keine Daten
Daniel Karp	Executive Vice President of Corporate Development	no data	keine Daten	0.0075% $ 295.9k
Aaron Falcione	Executive VP & Chief Human Resources Officer	3.4yrs	keine Daten	0.013% $ 499.0k
Vittorio Nisita	Executive VP & Head of Global Business Services	3.4yrs	keine Daten	0.0096% $ 378.2k

3.4yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrenes Management: 0A9WDas Führungsteam des Unternehmens gilt als erfahren (3.4 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Kevin Ali	CEO & Director	3.4yrs	US$14.83m	0.056% $ 2.2m
Carrie Cox	Independent Chairman of the Board	3.4yrs	US$450.00k	keine Daten
Robert Essner	Independent Director	3.4yrs	US$335.00k	keine Daten
Rochelle Lazarus	Independent Director	3.4yrs	US$320.00k	0.00025% $ 9.8k
Martha McGarry	Independent Director	3.4yrs	US$320.00k	keine Daten
R. Alan Ezekowitz	Independent Director	3.4yrs	US$330.00k	keine Daten
Helene Gayle	Independent Director	3.4yrs	US$320.00k	keine Daten
Shalini Sharp	Independent Director	3.4yrs	US$345.00k	0% $ 0
Philip Ozuah	Independent Director	3.4yrs	US$320.00k	keine Daten
Cynthia Patton	Independent Director	3.4yrs	US$330.00k	keine Daten
Grace Whiteford	Independent Director	3.4yrs	US$320.00k	0% $ 0
Deborah Leone	Independent Director	3.4yrs	US$330.00k	0% $ 0

3.4yrs

Durchschnittliche Betriebszugehörigkeit

64yo

Durchschnittliches Alter

Erfahrener Vorstand: 0A9WDie Vorstandsmitglieder gelten als erfahren (3.4 Jahre durchschnittliche Amtszeit).

Organon Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Organon & Co., Annual General Meeting, Jun 04, 2024

Organon & Co. Announces Departure of Sandra Milligan as Head of Research and Development Effective January 5, 2024

Organon Announces Two Leadership Appointments

Organon & Co. Appoints Kirke Weaver as General Counsel and Corporate Secretary, Effective January 1, 2023

Organon & Co. Announces Resignation of Deborah H. Telman as Executive Vice President, General Counsel and Corporate Secretary, Effective July 22, 2022

Organon & Co. Appoints Meghan Rivera as US Managing Director, Organon

Recent updates

Organon & Co. Updates on FDA Review of VTAMA (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Third quarter dividend of US$0.28 announced

Organon & Co. Revises Earnings Guidance for the Full Year 2024

Third quarter 2024 earnings released: EPS: US$1.39 (vs US$0.23 in 3Q 2023)

Organon & Co. (NYSE:OGN) completed the acquisition of Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others.

Organon & Co. to Report Q3, 2024 Results on Oct 31, 2024

Shanghai Henlius Biotech, Inc. and Organon Announces Phase 3 Comparative Clinical Study of Perjeta®? (pertuzumab) Biosimilar Candidate HLX11

Organon & Co. (NYSE:OGN) agreed to acquire Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others for approximately $1.2 billion.

Second quarter dividend of US$0.28 announced

Second quarter 2024 earnings released: EPS: US$0.76 (vs US$0.95 in 2Q 2023)

Organon & Co. Affirms Revenue Guidance for the Full Year 2024

Investor sentiment deteriorates as stock falls 18%

Organon & Co. to Report Q2, 2024 Results on Aug 06, 2024

Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14

First quarter dividend of US$0.28 announced

First quarter 2024 earnings released: EPS: US$0.79 (vs US$0.70 in 1Q 2023)

Organon & Co. Provides Earnings Guidance for the Year 2023

Organon & Co., Annual General Meeting, Jun 04, 2024

Organon & Co. to Report Q1, 2024 Results on May 02, 2024

US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary

Fourth quarter dividend of US$0.28 announced

Full year 2023 earnings released: EPS: US$4.01 (vs US$3.61 in FY 2022)

Organon & Co. Declares Quarterly Dividend, Payable on March 14, 2024

Organon & Co. to Report Q4, 2023 Results on Feb 15, 2024

Investor sentiment improves as stock rises 21%

Organon’S Xaciato (Clindamycin Phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis in Females Aged 12 and Older

Organon & Co. Announces Departure of Sandra Milligan as Head of Research and Development Effective January 5, 2024

Investor sentiment deteriorates as stock falls 17%

Samsung Bioepis & Organon Announces FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (Adalimumab-bwwd)

Organon & Co. Declares a Quarterly Dividend, Payable on December 14, 2023

Third quarter 2023 earnings released: EPS: US$0.23 (vs US$0.89 in 3Q 2022)

Organon & Co. to Report Q3, 2023 Results on Nov 02, 2023

Organon & Co.(NYSE:OGN) dropped from FTSE All-World Index (USD)

Organon Announces First Real-World Observational Study of the JADA® System

Organon Announces Two Leadership Appointments

Organon & Co. Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.95 (vs US$0.92 in 2Q 2022)

Samsung Bioepis & Organon Announces Topline Results from Interchangeability Study of SB5 Humira Biosimilar

Organon & Co. to Report Q2, 2023 Results on Aug 08, 2023

Organon & Co. & Samsungbioepis Co,.Ltd Announces US Launch of Humira Biosimilar Hadlima (adalimumab-Bwwd) in Multiple Presentations Consistent with Originator

Organon & Co. Declares Guidance Quarterly Dividend, Payable on June 15, 2023

First quarter 2023 earnings released: EPS: US$0.70 (vs US$1.37 in 1Q 2022)

Full year 2022 earnings released: EPS: US$3.61 (vs US$5.33 in FY 2021)

Organon Declares Quarterly Dividend, Payable on March 16, 2023

Organon & Co. to Report Q4, 2022 Results on Feb 16, 2023

Organon & Co. Appoints Kirke Weaver as General Counsel and Corporate Secretary, Effective January 1, 2023

Organon Canada Launches Ontruzant®, A Biosimilar of the Reference Biologic Herceptin®, Providing Patients in Canada with Certain Breast and Gastric Cancers with an Additional Therapeutic Option At A Lower Cost

Organon Canada Launches Aybintio Providing New Option at Reduced Cost for Canadians Living with Certain Aggressive Forms of Cancer

Third quarter 2022 earnings released: EPS: US$0.89 (vs US$1.27 in 3Q 2021)

Organon & Co. Revises Earnings Guidance for the Full Year 2022

Organon & Co. to Report Q3, 2022 Results on Nov 03, 2022

Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration Humira® Biosimilar Hadlima™

Second quarter 2022 earnings released: EPS: US$0.92 (vs US$1.70 in 2Q 2021)

Organon & Co. Declares Quarterly Dividend, Payable on September 15, 2022

Organon & Co. to Report Q2, 2022 Results on Aug 04, 2022

Organon & Co. Announces Resignation of Deborah H. Telman as Executive Vice President, General Counsel and Corporate Secretary, Effective July 22, 2022

First quarter 2022 earnings released: EPS: US$1.37 (vs US$1.56 in 1Q 2021)

Organon & Co. Declares Quarterly Dividend, Payable on June 16, 2022

Organon & Co. to Report Q1, 2022 Results on May 05, 2022

Investor sentiment deteriorated over the past week

Organon & Co. Appoints Meghan Rivera as US Managing Director, Organon

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Organon & Co. Provides Earnings Guidance for Full Year 2022

Organon & Co. to Report Q4, 2021 Results on Feb 17, 2022

Samsung Bioepis Co., Ltd. and Organon & Co. announce the U.S. Food and Drug Administration accept for review the supplemental Biologics License Application

Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others.

Independent Director recently bought US$101k worth of stock

Organon & Co. Declares Inaugural Quarterly Dividend, Payable on September 13, 2021

Analyse der Geschäftsführervergütung